Puma Biotechnology (NASDAQ: PBYI) used to be a pretty compelling investment for many biotech investors out there. Its only drug, Nerlynx (also known as neratinib), targets a significant portion of the breast cancer patient population and definitely has the potential to be a lucrative drug. However, the company seems to have taken a major turn for the worse over the past year.
While bad news has sent share prices falling by around two-thirds in the past 12 months, some investors think that the company is now a cheap buy, especially since it still boasts significant revenue figures for its meager $325 million market cap.
Let's take a closer look at whether you should consider buying into Puma, or if you should stay clear of this stock.
Source Fool.com